Global Blood Therapeutics, Inc. (GBT) financial statements (2020 and earlier)

Company profile

Business Address 171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments302275315147149
Cash and cash equivalents30227519892149
Short-term investments  11655 
Receivables3    
Inventory, net of allowances, customer advances and progress billings1    
Inventory1    
Prepaid expense96421
Other current assets 2611
Other undisclosed current assets312202   
Total current assets:628486324150151
Noncurrent Assets
Operating lease, right-of-use asset53
Property, plant and equipment27151722
Long-term investments and receivables  1550 
Long-term investments  1550 
Restricted cash and investments22100
Other noncurrent assets100  
Other undisclosed noncurrent assets85114   
Total noncurrent assets:16813232532
TOTAL ASSETS:796618357202153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7033261510
Accounts payable116743
Accrued liabilities41171054
Employee-related liabilities1810952
Other liabilities21011
Total current liabilities:7134261611
Noncurrent Liabilities
Long-term debt and lease obligation146    
Long-term debt, excluding current maturities74    
Operating lease, liability72
Liabilities, other than long-term debt0111212
Other liabilities0111212
Total noncurrent liabilities:146111212
Total liabilities:21745381612
Stockholders' equity
Stockholders' equity attributable to parent579573319186141
Common stock00000
Additional paid in capital1,3171,045617367239
Accumulated other comprehensive income (loss)1(0)(0)(0) 
Accumulated deficit(739)(472)(298)(181)(98)
Total stockholders' equity:579573319186141
TOTAL LIABILITIES AND EQUITY:796618357202153

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net  0
Gross profit:2   0
Operating expenses(292)(183)(119)(83)(46)
Other undisclosed operating income (loss)8   (0)
Operating loss:(281)(183)(119)(83)(46)
Nonoperating income
(Investment Income, Nonoperating)
    0
Interest and debt expense(31)    
Loss from continuing operations before equity method investments, income taxes:(313)(183)(119)(83)(46)
Other undisclosed income from continuing operations before income taxes46921 
Net loss:(267)(174)(117)(82)(46)
Other undisclosed net loss attributable to parent(0)(0)   
Net loss attributable to parent:(267)(174)(117)(82)(46)
Other undisclosed net loss available to common stockholders, basic    (4)
Net loss available to common stockholders, diluted:(267)(174)(117)(82)(51)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(267)(174)(117)(82)(46)
Comprehensive loss:(267)(174)(117)(82)(46)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(266)(174)(117)(83)(46)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: